Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hepion Pharmaceuticals, Inc. (HEPA)
USD0.06
-0.01 (-8.33%)
US OTC Healthcare Biotechnology
Address
399 Thornall Street 8837
Edison, NJ, US
Edison, NJ, US
CEO
Gary S. Stetz
Website
hepionpharma.com
IPO
2014-02-10
CIK 1583771 ISIN US4268974015
Description
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.06
-0.01 (-8.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
22.2K
Beta
1.66
Float Shares
11.62M
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.11% | +54.39% | +83.33% | +46.67% | +23.94% | +46.67% | -27.87% | -99.97% | -99.99% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Hold
Price Targets & DCF
Current price
0.06
Low
70.00
+127,172.7%
Consensus
70.00
+127,172.7%
Median
70.00
+127,172.7%
High
70.00
+127,172.7%
DCF (Unlevered)
0.17
+214.4%
DCF (Levered)
0.19
+242.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
70.00
+127,172.7%
|
Quality scores
Altman Z-Score
-129.79
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+99.2% ★ Q1'26: +96.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-923.7% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7,556.5% Q1'26: +309.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
est: 20.30M (-100.0%)
|
—
|
—
|
—
— – —
|
—
— – —
|
| EBITDA |
-14.58M
|
-14.88M
|
-8.25M
|
—
— – —
|
—
— – —
|
| EBIT |
-14.59M
|
-14.91M
|
-8.25M
|
—
— – —
|
—
— – —
|
| Net Income |
-9.45M
est: -8.95B (+99.9%)
|
-13.19M
est: -70.23M (+81.2%)
|
-8.28M
est: -2.94B (+99.7%)
|
-4.44B
-4.44B – -4.44B
-51.0% YoY
|
-4.40B
-4.40B – -4.40B
+0.8% YoY
|
| SGA |
7.00M
|
7.50M
|
3.32M
|
—
— – —
|
—
— – —
|
| EPS |
-97,353.00
est: -72,800.00 (-33.7%)
|
-107.35
est: -571.50 (+81.2%)
|
-0.88
est: -312.50 (+99.7%)
|
-472.00
-472.00 – -472.00
-51.0% YoY
|
-468.00
-468.00 – -468.00
+0.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
4
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NAME OF REPORTING PERSONS | 5.00M | 9.00% | — | 5.00M | — | 5.00M | — | Cayman Islands | 2021-02-19 | ↗ |
| 2 | Donald E. Garlikov | 3.41M | 16.57% | 3.41M | — | 3.41M | — | IN | USA | 2019-04-02 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 3.33M | 4.36% | — | 17.5K | 3.28M | 44.3K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 4 | (. | 1.17M | 4.00% | 1.17M | — | 1.17M | — | IN | United States | 2020-12-28 | ↗ |
| 5 | 27-4413262 | 1.17M | 4.00% | 1.17M | — | 1.17M | — | OO | Maryland | 2020-12-28 | ↗ |
| 6 | CVI Investments, Inc. | 420.0K | 1.30% | — | 420.0K | — | 420.0K | CO | Cayman Islands | 2021-02-16 | ↗ |
| 7 | Heights Capital Management, Inc. | 420.0K | 1.30% | — | 420.0K | — | 420.0K | CO | Cayman Islands | 2021-02-16 | ↗ |
| 8 | Armistice Capital, LLC | 418.0K | 8.67% | — | 418.0K | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 9 | Steven Boyd | 418.0K | 8.67% | — | 418.0K | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 10 | 2 | 359.9K | 9.90% | — | — | — | 359.9K | CO | Texas | 2019-06-28 | ↗ |
| 11 | Empery Asset Management, LP | 335.7K | 0.44% | — | 335.7K | — | 335.7K | PN | Delaware | 2022-01-19 | ↗ |
| 12 | Hudson Bay Capital Management LP | 295.9K | 0.92% | — | 295.9K | — | — | PN | State of Delaware | 2021-02-09 | ↗ |
| 13 | Sander Gerber | 295.9K | 0.92% | — | 295.9K | — | — | IN | United States | 2021-02-09 | ↗ |
| 14 | Heights Capital Management, Inc. | 183.5K | 5.00% | — | 183.5K | — | 183.5K | CO | Delaware | 2020-02-10 | ↗ |
| 15 | Inc. | 181.4K | 4.90% | — | 181.4K | — | 181.4K | FI, CO | — | 2020-02-14 | ↗ |
| 16 | Kassam | 181.4K | 4.90% | — | 181.4K | — | 181.4K | HC, IN | — | 2020-02-14 | ↗ |
| 17 | LLC | 181.4K | 4.90% | — | 181.4K | — | 181.4K | HC, OO | — | 2020-02-14 | ↗ |
| 18 | Management LP | 181.4K | 4.90% | — | 181.4K | — | 181.4K | IA, PN | — | 2020-02-14 | ↗ |
| 19 | Nathoo | 181.4K | 4.90% | — | 181.4K | — | 181.4K | HC, IN | — | 2020-02-14 | ↗ |
| 20 | Winson | 181.4K | 4.90% | — | 181.4K | — | 181.4K | HC, IN | — | 2020-02-14 | ↗ |
| 21 | Martin D. Hoe | 4.9K | 5.25% | — | 4.9K | — | — | IN | United States | 2021-02-18 | ↗ |
| 22 | Ryan M. Lane | 4.9K | 5.25% | — | 4.9K | — | — | IN | United States | 2021-02-18 | ↗ |
| 23 | Altium Capital Management, LP | — | 0.00% | — | — | — | — | IA, PN | Delaware, United States of America | 2022-02-14 | ↗ |
| 24 | Altium Growth Fund, LP | — | 0.00% | — | — | — | — | PN | Delaware, United States of America | 2022-02-14 | ↗ |
| 25 | Altium Growth GP, LLC | — | 0.00% | — | — | — | — | OO | Delaware, United States of America | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | XTX TOPCO LTD | — -17.4K (-100.0%) | — -1.4K (-100.0%) | 0.00% -0.612 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 9.37 | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
390.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+390,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | Stetz Gary S. | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,250,000 | 0.04 | 50.0K | 1,250,000 | I | ↗ |
| 2026-04-21 | Purcell Michael J. | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,250,000 | 0.04 | 50.0K | 1,250,000 | D | ↗ |
| 2026-04-21 | LoPriore Vincent S | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,250,000 | 0.04 | 50.0K | 6,250,000 | I | ↗ |
| 2026-04-21 | Appajosyula Sireesh | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,250,000 | 0.04 | 50.0K | 1,250,000 | D | ↗ |
| 2026-03-16 | Stetz Gary S. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-16 | LoPriore Vincent S | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-16 | Appajosyula Sireesh | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-06 | Purcell Michael J. | Director | A-Award | A | Restricted Stock Units | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2024-03-05 | Purcell Michael J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-19 | Lbiati Kaouthar | Director | A-Award | A | Stock Options | 85,000 | 2.56 | 217.6K | 88,000 | — | ↗ |
| 2024-02-19 | JACOB GARY S | Director | A-Award | A | Stock Options | 85,000 | 2.56 | 217.6K | 102,120 | — | ↗ |
| 2024-02-19 | Block Timothy M. | Director | A-Award | A | Stock Options | 85,000 | 2.56 | 217.6K | 99,562 | — | ↗ |
| 2024-02-19 | BRANCACCIO JOHN P | Director / Officer | A-Award | A | Stock Options | 85,000 | 2.56 | 217.6K | 99,563 | — | ↗ |
| 2023-11-27 | Wijngaard Peter | Director | P-Purchase | A | Common Stock | 2,500 | 3.05 | 7.6K | 9,501 | — | ↗ |
| 2023-11-24 | Wijngaard Peter | Director | P-Purchase | A | Common Stock | 2,500 | 3.09 | 7.7K | 7,001 | — | ↗ |
| 2023-09-19 | Wijngaard Peter | Director | P-Purchase | A | Common Stock | 1,000 | 5.64 | 5.6K | 4,501 | — | ↗ |
| 2023-09-18 | Foster Robert T | Director / Officer | P-Purchase | A | Common Stock | 1,600 | 5.60 | 9.0K | 50,470 | — | ↗ |
| 2023-09-15 | Wijngaard Peter | Director | P-Purchase | A | Common Stock | 861 | 5.37 | 4.6K | 3,501 | — | ↗ |
| 2023-09-15 | Foster Robert T | Director / Officer | P-Purchase | A | Common Stock | 1,600 | 5.40 | 8.6K | 48,870 | — | ↗ |
| 2022-06-27 | Reddi Anand | Director | — | D | Stock Options | 60,000 | 0.69 | 41.4K | 0 | — | ↗ |
| 2022-06-27 | Lbiati Kaouthar | Director | — | D | Stock Options | 60,000 | 0.69 | 41.4K | 0 | — | ↗ |
| 2021-05-18 | Wijngaard Peter | Director | A-Award | A | Stock Options | 200,000 | 1.70 | 340.0K | 260,000 | — | ↗ |
| 2021-05-18 | Lippa Arnold | Director | A-Award | A | Stock Options | 200,000 | 1.70 | 340.0K | 291,110 | — | ↗ |
| 2021-05-18 | JACOB GARY S | Director | A-Award | A | Stock Options | 250,000 | 1.70 | 425.0K | 342,785 | — | ↗ |
| 2021-05-18 | Foster Robert T | Director / Officer | A-Award | A | Stock Options | 1,900,000 | 1.70 | 3.23M | 2,501,879 | — | ↗ |
| 2021-05-18 | Cavan John T | Officer | A-Award | A | Stock Options | 1,200,000 | 1.70 | 2.04M | 1,581,060 | — | ↗ |
| 2021-05-18 | Block Timothy M. | Director | A-Award | A | Stock Options | 200,000 | 1.70 | 340.0K | 291,276 | — | ↗ |
| 2021-05-18 | BRANCACCIO JOHN P | Director | A-Award | A | Stock Options | 200,000 | 1.70 | 340.0K | 291,332 | — | ↗ |
| 2021-05-18 | ADAMS THOMAS PHD | Director | A-Award | A | Stock Options | 200,000 | 1.70 | 340.0K | 291,050 | — | ↗ |
| 2021-02-18 | Foster Robert T | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 2.00 | 40.0K | 45,259 | — | ↗ |
| 2021-02-18 | Cavan John T | Officer | P-Purchase | A | Common Stock | 10,000 | 2.00 | 20.0K | 14,800 | — | ↗ |
| 2021-02-16 | Wijngaard Peter | Director | P-Purchase | A | Common Stock | 10,000 | 2.20 | 22.0K | 30,000 | — | ↗ |
| 2020-12-18 | Wijngaard Peter | Director | P-Purchase | A | Common Stock | 20,000 | 1.91 | 38.2K | 20,000 | — | ↗ |
| 2020-12-08 | Foster Robert T | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 1.58 | 39.4K | 25,259 | — | ↗ |
| 2020-12-02 | BRANCACCIO JOHN P | Director | P-Purchase | A | Common Stock | 7,000 | 1.53 | 10.7K | 7,008 | — | ↗ |
| 2020-12-01 | JACOB GARY S | Director | P-Purchase | A | Common Stock | 12,000 | 1.66 | 19.9K | 12,059 | — | ↗ |
| 2020-11-25 | Cavan John T | Officer | P-Purchase | A | Common Stock | 4,500 | 1.62 | 7.3K | 4,800 | — | ↗ |
| 2020-08-19 | Wijngaard Peter | Director | A-Award | A | Stock Options | 30,000 | 3.72 | 111.6K | 60,000 | — | ↗ |
| 2020-08-19 | Lippa Arnold | Director | A-Award | A | Stock Options | 30,000 | 3.72 | 111.6K | 91,110 | — | ↗ |
| 2020-08-19 | JACOB GARY S | Director | A-Award | A | Stock Options | 30,000 | 3.72 | 111.6K | 92,785 | — | ↗ |
| 2020-08-19 | Foster Robert T | Director / Officer | A-Award | A | Stock Options | 212,000 | 3.72 | 788.6K | 601,879 | — | ↗ |
| 2020-08-19 | Cavan John T | Officer | A-Award | A | Stock Options | 160,000 | 3.72 | 595.2K | 381,060 | — | ↗ |
| 2020-08-19 | Block Timothy M. | Director | A-Award | A | Stock Options | 30,000 | 3.72 | 111.6K | 91,276 | — | ↗ |
| 2020-08-19 | BRANCACCIO JOHN P | Director | A-Award | A | Stock Options | 30,000 | 3.72 | 111.6K | 91,332 | — | ↗ |
| 2020-08-19 | ADAMS THOMAS PHD | Director | A-Award | A | Stock Options | 30,000 | 3.72 | 111.6K | 91,050 | — | ↗ |
| 2020-06-25 | Wijngaard Peter | Director | A-Award | A | Stock Options | 30,000 | 2.73 | 81.9K | 30,000 | — | ↗ |
| 2020-06-10 | Wijngaard Peter | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-03 | Lippa Arnold | Director | A-Award | A | Stock Options | 60,000 | 1.63 | 97.8K | 61,109 | — | ↗ |
| 2020-04-03 | JACOB GARY S | Director | A-Award | A | Stock Options | 60,000 | 1.63 | 97.8K | 62,729 | — | ↗ |
| 2020-04-03 | Foster Robert T | Director / Officer | A-Award | A | Stock Options | 380,000 | 1.63 | 619.4K | 389,879 | — | ↗ |
| 2020-04-03 | Cavan John T | Officer | A-Award | A | Stock Options | 215,000 | 1.63 | 350.5K | 221,059 | — | ↗ |
| 2020-04-03 | Block Timothy M. | Director | A-Award | A | Stock Options | 60,000 | 1.63 | 97.8K | 61,220 | — | ↗ |
| 2020-04-03 | BRANCACCIO JOHN P | Director | A-Award | A | Stock Options | 60,000 | 1.63 | 97.8K | 61,275 | — | ↗ |
| 2020-04-03 | ADAMS THOMAS PHD | Director | A-Award | A | Stock Option | 60,000 | 1.63 | 97.8K | 61,051 | — | ↗ |
| 2019-07-24 | Lippa Arnold | Director | A-Award | A | Stock Options | 970 | 3.24 | 3.1K | 1,109 | — | ↗ |
| 2019-07-24 | JACOB GARY S | Director | A-Award | A | Stock Options | 970 | 3.24 | 3.1K | 2,729 | — | ↗ |
| 2019-07-24 | Foster Robert T | Director / Officer | A-Award | A | Stock Options | 9,700 | 3.24 | 31.4K | 9,879 | — | ↗ |
| 2019-07-24 | Cavan John T | Officer | A-Award | A | Stock Options | 5,820 | 3.24 | 18.9K | 6,059 | — | ↗ |
| 2019-07-24 | Block Timothy M. | Director | A-Award | A | Stock Options | 970 | 3.24 | 3.1K | 1,220 | — | ↗ |
| 2019-07-24 | BRANCACCIO JOHN P | Director | A-Award | A | Stock Options | 970 | 3.24 | 3.1K | 1,275 | — | ↗ |
| 2019-07-24 | ADAMS THOMAS PHD | Director | A-Award | A | Stock Options | 970 | 3.24 | 3.1K | 1,051 | — | ↗ |
| 2019-03-15 | Garlikov Donald E | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,320,000 | — | ↗ |
| 2018-07-03 | Lippa Arnold | Director | P-Purchase | A | Series C Convertible Preferred Stock | 15 | 1.55 | 23.25 | 15 | — | ↗ |
| 2018-07-03 | JACOB GARY S | Director | P-Purchase | A | Warrants | 8,625 | 1.55 | 13.4K | 8,625 | — | ↗ |
| 2018-07-03 | Cavan John T | Officer | P-Purchase | A | Warrants | 8,625 | 1.55 | 13.4K | 8,625 | — | ↗ |
| 2018-07-03 | BRANCACCIO JOHN P | Director | P-Purchase | A | Warrants | 1,725 | 1.55 | 2.7K | 1,725 | — | ↗ |
| 2018-01-03 | SAPIRSTEIN JAMES | Director / Officer | A-Award | A | Common Stock | 322,092 | 0.00 | — | 492,819 | — | ↗ |
| 2018-01-03 | Foster Robert T | Officer | A-Award | A | Common Stock | 100,654 | 0.00 | — | 144,736 | — | ↗ |
| 2018-01-03 | Cavan John T | Officer | A-Award | A | Common Stock | 101,221 | 0.00 | — | 167,947 | — | ↗ |
| 2017-07-20 | Cavan John T | Officer | A-Award | A | Stock Options | 15,000 | 0.58 | 8.7K | 133,688 | — | ↗ |
| 2017-07-06 | Sullivan-Bolyai John Z | Officer | A-Award | A | Common Stock | 58,681 | 0.00 | — | 58,681 | — | ↗ |
| 2017-07-06 | SAPIRSTEIN JAMES | Director / Officer | A-Award | A | Common Stock | 141,061 | 0.00 | — | 170,727 | — | ↗ |
| 2017-07-06 | Foster Robert T | Officer | A-Award | A | Common Stock | 44,082 | 0.00 | — | 44,082 | — | ↗ |
| 2017-07-06 | Cavan John T | Officer | A-Award | A | Common Stock | 46,726 | 0.00 | — | 66,726 | — | ↗ |
| 2017-06-20 | Cavan John T | Officer | P-Purchase | A | Common Stock | 20,000 | 0.65 | 13.0K | 20,000 | — | ↗ |
| 2017-04-28 | Garlikov Donald E | 10% Owner | — | D | Warrants | 31,250 | 10.00 | 312.5K | 0 | — | ↗ |
| 2017-04-10 | HOWSON TAMAR D | Director | A-Award | A | Stock Options | 35,000 | 1.60 | 56.0K | 80,000 | — | ↗ |
| 2017-03-06 | SAPIRSTEIN JAMES | Director / Officer | A-Award | A | Stock Options | 313,898 | 1.48 | 464.6K | 2,761,129 | — | ↗ |
| 2017-03-03 | SAPIRSTEIN JAMES | Director / Officer | A-Award | A | Stock Options | 313,898 | 1.43 | 448.9K | 2,447,231 | — | ↗ |
| 2016-12-14 | HOWSON TAMAR D | Director | — | D | Stock Options | 45,000 | 2.01 | 90.5K | 0 | — | ↗ |
| 2016-10-27 | SAPIRSTEIN JAMES | Director / Officer | M-Exempt | D | Stock Options | 16,666 | 1.50 | 25.0K | 2,133,334 | — | ↗ |
| 2016-09-20 | ADAMS THOMAS PHD | Director | — | D | Stock Options | 45,000 | 1.12 | 50.4K | 0 | — | ↗ |
| 2016-08-26 | Sullivan-Bolyai John Z | Officer | A-Award | A | Stock Options | 135,790 | 1.10 | 149.4K | 290,790 | — | ↗ |
| 2016-08-26 | Cavan John T | Officer | A-Award | A | Stock Options | 18,688 | 1.10 | 20.6K | 118,688 | — | ↗ |
| 2016-08-17 | CERRONE GABRIEL | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 78,146 | — | ↗ |
| 2016-07-19 | Lippa Arnold | Director | A-Award | A | Stock Options | 32,500 | 1.04 | 33.8K | 77,500 | — | ↗ |
| 2016-07-19 | JACOB GARY S | Director | A-Award | A | Stock Options | 65,000 | 1.04 | 67.6K | 1,015,000 | — | ↗ |
| 2016-07-19 | Block Timothy M. | Director | A-Award | A | Stock Options | 65,000 | 1.04 | 67.6K | 169,688 | — | ↗ |
| 2016-07-19 | BRANCACCIO JOHN P | Director | A-Award | A | Stock Options | 65,000 | 1.04 | 67.6K | 200,656 | — | ↗ |
| 2016-06-13 | Sullivan-Bolyai John Z | Officer | A-Award | A | Stock Options | 20,000 | 0.99 | 19.8K | 155,000 | — | ↗ |
| 2016-06-13 | SAPIRSTEIN JAMES | Director / Officer | A-Award | A | Stock Options | 500,000 | 0.99 | 495.0K | 2,150,000 | — | ↗ |
| 2016-06-10 | Foster Robert T | Officer | — | D | Stock Options | 100,000 | 0.92 | 92.0K | 0 | — | ↗ |
| 2016-04-04 | Garlikov Donald E | 10% Owner | — | I | Warrants | 31,250 | 13.60 | 425.0K | 0 | — | ↗ |
| 2016-04-01 | Cavan John T | Officer | — | D | Stock Options | 100,000 | 1.21 | 121.0K | 0 | — | ↗ |
| 2016-03-02 | Sullivan-Bolyai John Z | Officer | — | D | Stock Options | 135,000 | 2.56 | 345.6K | 0 | — | ↗ |
| 2016-02-18 | SAPIRSTEIN JAMES | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.00 | 10.0K | 13,000 | — | ↗ |
| 2015-11-30 | SAPIRSTEIN JAMES | Director / Officer | P-Purchase | A | Common Stock | 500 | 2.15 | 1.1K | 3,000 | — | ↗ |
| 2015-11-30 | Lippa Arnold | Director | — | D | Stock Options | 45,000 | 2.16 | 97.2K | 0 | — | ↗ |
| 2015-11-23 | SAPIRSTEIN JAMES | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 1.64 | 4.1K | 2,500 | — | ↗ |
| 2015-10-13 | Garlikov Donald E | 10% Owner | — | D | Warrants | 31,250 | 34.00 | 1.06M | 0 | — | ↗ |
| 2015-06-04 | SAPIRSTEIN JAMES | Director / Officer | A-Award | A | Stock Options | 150,000 | 3.60 | 540.0K | 1,650,000 | — | ↗ |
| 2015-06-04 | Hornung William Karl | Officer | A-Award | A | Stock Options | 15,000 | 3.60 | 54.0K | 165,000 | — | ↗ |
| 2014-12-03 | SAPIRSTEIN JAMES | Director / Officer | A-Award | A | Stock Options | 500,000 | 1.50 | 750.0K | 1,500,000 | — | ↗ |
| 2014-12-03 | McGuigan Christopher | Director | A-Award | A | Stock Options | 118,638 | 1.50 | 178.0K | 415,234 | — | ↗ |
| 2014-12-03 | JACOB GARY S | Director | A-Award | A | Stock Options | 420,000 | 1.50 | 630.0K | 950,000 | — | ↗ |
| 2014-12-03 | Hornung William Karl | Officer | A-Award | A | Stock Options | 50,000 | 1.50 | 75.0K | 150,000 | — | ↗ |
| 2014-12-03 | Block Timothy M. | Director | A-Award | A | Stock Options | 29,911 | 1.50 | 44.9K | 104,688 | — | ↗ |
| 2014-12-03 | BRANCACCIO JOHN P | Director | A-Award | A | Stock Options | 38,759 | 1.50 | 58.1K | 135,656 | — | ↗ |
| 2014-06-23 | Hornung William Karl | Officer | — | D | Stock Options | 100,000 | 1.70 | 170.0K | 0 | — | ↗ |
| 2014-04-03 | Denoyer Bernard | Officer | A-Award | A | Stock Options | 20,000 | 2.35 | 47.0K | 40,000 | — | ↗ |
| 2014-04-03 | Block Timothy M. | Director | A-Award | A | Stock Options | 15,000 | 2.35 | 35.3K | 74,777 | — | ↗ |
| 2014-04-03 | BRANCACCIO JOHN P | Director | A-Award | A | Stock Options | 15,000 | 2.35 | 35.3K | 96,897 | — | ↗ |
| 2014-03-19 | SAPIRSTEIN JAMES | Director / Officer | — | D | Stock Options | 1,000,000 | 2.31 | 2.31M | 0 | — | ↗ |
| 2014-03-19 | JACOB GARY S | Director | A-Award | A | Stock Options | 300,000 | 2.31 | 693.0K | 530,000 | — | ↗ |
| 2014-03-12 | McGuigan Christopher | Director | A-Award | A | Stock Options | 16,596 | 2.37 | 39.3K | 296,596 | — | ↗ |
| 2014-03-12 | Block Timothy M. | Director | A-Award | A | Stock Options | 19,777 | 2.37 | 46.9K | 59,777 | — | ↗ |
| 2014-03-12 | BRANCACCIO JOHN P | Director | A-Award | A | Stock Options | 21,897 | 2.37 | 51.9K | 81,897 | — | ↗ |
| 2014-03-04 | BRANCACCIO JOHN P | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 4,393 | 1.49 | 6.5K | 6,408 | — | ↗ |
| 2014-02-18 | SYNERGY PHARMACEUTICALS, INC. | 10% Owner | J-Other | D | Common Stock, par value $0.0001 per share | 9,000,000 | 0.00 | — | 0 | — | ↗ |
| 2014-02-18 | JACOB GARY S | Director / Officer | J-Other | A | Common Stock, par value $0.0001 per share | 32,935 | 0.00 | — | 32,935 | — | ↗ |
| 2014-02-18 | Denoyer Bernard | Officer | J-Other | A | Common Stock, par value $0.0001 per share | 1,030 | 0.00 | — | 1,030 | — | ↗ |
| 2014-02-18 | BRANCACCIO JOHN P | Director | J-Other | A | Common Stock, par value $0.0001 per share | 2,015 | 0.00 | — | 2,015 | — | ↗ |
| 2014-01-24 | McGuigan Christopher | Director | A-Award | A | Stock Options | 250,000 | 0.37 | 92.5K | 280,000 | — | ↗ |
| 2014-01-24 | JACOB GARY S | Director / Officer | A-Award | A | Stock Options | 200,000 | 0.37 | 74.0K | 230,000 | — | ↗ |
| 2014-01-24 | Denoyer Bernard | Director | A-Award | A | Stock Options | 10,000 | 0.37 | 3.7K | 20,000 | — | ↗ |
| 2014-01-24 | Block Timothy M. | Director | A-Award | A | Stock Options | 10,000 | 0.37 | 3.7K | 40,000 | — | ↗ |
| 2014-01-24 | BRANCACCIO JOHN P | Director | A-Award | A | Stock Options | 30,000 | 0.37 | 11.1K | 60,000 | — | ↗ |
| 2013-11-26 | Denoyer Bernard | Officer | A-Award | A | Stock Options | 10,000 | 0.11 | 1.1K | 10,000 | — | ↗ |
| 2013-11-26 | Block Timothy M. | Director | — | D | Stock Options | 30,000 | 0.11 | 3.3K | 0 | — | ↗ |
| 2013-10-07 | SYNERGY PHARMACEUTICALS, INC. | 10% Owner | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 9,000,000 | — | ↗ |
| 2013-10-07 | Denoyer Bernard | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-10-02 | McGuigan Christopher | Director | — | D | Stock Options | 30,000 | 0.11 | 3.3K | 0 | — | ↗ |
| 2013-10-02 | JACOB GARY S | Director / Officer | — | D | Stock Options | 30,000 | 0.11 | 3.3K | 0 | — | ↗ |
| 2013-10-02 | BRANCACCIO JOHN P | Director | — | D | Stock Options | 30,000 | 0.11 | 3.3K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
11.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | John Brancaccio Former Interim Chief Executive Officer and Chief Financial Officer | 232.5K | — | — | — | — | — | 232.5K | 0.00% | ↗ |
| 2 | 2025 | Kaouthar Lbiati, M.D. Former Chief Executive Officer | 198.0K | — | — | — | — | — | 198.0K | 0.00% | ↗ |
| 3 | 2024 | John Brancaccio Former Interim Chief Executive Officer and Chief Financial Officer | 313.9K | — | — | 188.4K | — | — | 502.3K | 37.51% | ↗ |
| 4 | 2014 | James Sapirstein Chief Executive Officer | 86.2K | — | — | — | — | — | 1.26M | 0.00% | ↗ |
| 5 | 2014 | Gary S. Jacob, Ph.D. Chairman of the Board and former Chief Executive Officer | — | — | — | — | — | — | 274.2K | 0.00% | ↗ |
| 6 | 2014 | William Hornung Chief Financial Officer | 4.9K | — | — | — | — | — | 80.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gary S. Stetz | Interim Chief Executive Officer & Director | 85.5K | male |
| Kaouthar Lbiati | CEO & Director | 85.5K | — |
| Sharen Pyatetskaya | Director of Investor Relations | — | — |
| Vincent LoPriore | Executive Chairman | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HEPA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
